1887

Abstract

subsp. Typhi ( Typhi) Vi antigen capsular polysaccharide (Vi-CPS) is a licensed vaccine against typhoid fever. As there is no animal model for Typhi fever to evaluate the protective efficacy of the Vi-CPS vaccine, a serum bactericidal assay (SBA) is the recommended ‘gold standard’ to evaluate its potency. Vi-CPS was extracted from Typhi Ty6S (CSBPI-B191) using a modified Gotschlich method. Purified Vi-CPS (50 µg) was injected intramuscularly into three groups of five rabbits; group 2 received an additional booster dose of 50 µg Vi-CPS on day 15 and group 3 received two additional boosters on days 15 and 30. The sera obtained from each group were tested by SBA on days 0, 15, 30 and 45. The anti-Vi-CPS titres for groups 1, 2 and 3 on days 15, 30 and 45 were 4, 16 and 16; 4, 32 and 32; and 16, 64 and 64, respectively. Thus, Vi-CPS was shown to be a potent immunogen, as even one dose could induce an efficient bactericidal effect against Typhi. Although Vi-CPS is a reliable vaccine, sometimes depolymerization during purification can affect its potency, which can be resolved through a potency test. As the passive haemagglutination test recommended by the World Health Organization does not indicate vaccine potency, we recommend using an SBA to evaluate the bactericidal ability of Vi-CPS.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.047159-0
2013-02-01
2019-10-19
Loading full text...

Full text loading...

/deliver/fulltext/jmm/62/2/283.html?itemId=/content/journal/jmm/10.1099/jmm.0.047159-0&mimeType=html&fmt=ahah

References

  1. Acharya I. L. , Lowe C. U. , Thapa R. , Gurubacharya V. L. , Shrestha M. B. , Cadoz M. , Schulz D. , Armand J. , Bryla D. A. . & other authors ( 1987; ). Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella Typhi. A preliminary report. . N Engl J Med 317:, 1101–1104. [CrossRef] [PubMed]
    [Google Scholar]
  2. Ahmadi H. , Tabaraie B. , Nejati M. , Al-e-Agha S. . ( 1999; ). Molecular characterization and optimization of Vi-capsular polysaccharide of Salmonella Typhi Ty6s production in bioreactor. . Med J Islam Repub Iran 13:, 37–42.
    [Google Scholar]
  3. Canh D. G. , Lin F. Y. , Thiem V. D. , Trach D. D. , Trong N. D. , Mao N. D. , Hunt S. , Schneerson R. , Robbins J. B. . & other authors ( 2004; ). Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children. . Infect Immun 72:, 6586–6588. [CrossRef] [PubMed]
    [Google Scholar]
  4. Chibber S. , Bhardwaj S. B. . ( 2004; ). Protection in a mouse peritonitis model mediated by iron-regulated outer-membrane protein of Salmonella typhi coupled to its Vi antigen. . J Med Microbiol 53:, 705–709. [CrossRef] [PubMed]
    [Google Scholar]
  5. Fadeel M. A. , Crump J. A. , Mahoney F. J. , Nakhla I. A. , Mansour A. M. , Reyad B. , El Melegi D. , Sultan Y. , Mintz E. D. , Bibb W. F. . ( 2004; ). Rapid diagnosis of typhoid fever by enzyme-linked immunosorbent assay detection of Salmonella serotype Typhi antigens in urine. . Am J Trop Med Hyg 70:, 323–328.[PubMed]
    [Google Scholar]
  6. Frantz I. D. . ( 1942; ). Growth requirements of the Meningococcus . . J Bacteriol 43:, 757–761.[PubMed]
    [Google Scholar]
  7. Gotschlich E. C. . ( 1975; ). Development of polysaccharide vaccines for the prevention of meningococcal diseases. . Monogr Allergy 9:, 245–258.[PubMed]
    [Google Scholar]
  8. Hestrin S. . ( 1949; ). The reaction of acetylcholine and other carboxylic acid derivatives with hydroxylamine, and its analytical application. . J Biol Chem 180:, 249–261.[PubMed]
    [Google Scholar]
  9. Holst J. , Feiring B. , Fuglesang J. E. , Høiby E. A. , Nøkleby H. , Aaberge I. S. , Rosenqvist E. . ( 2003; ). Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. . Vaccine 21:, 734–737. [CrossRef] [PubMed]
    [Google Scholar]
  10. Hudson L. , Hay F. . ( 1989; ). Practical Immunology, , 3rd edn.. Oxford:: Blackwell Scientific Publishers;
    [Google Scholar]
  11. Kasi A. M. . ( 1964; ). Physical and chemical studies of two dried inactivated typhoid vaccines (Vaccines K and L). . Bull World Health Organ 30:, 647–652.[PubMed]
    [Google Scholar]
  12. Kim Y.-R. , Yoo J. H. , Hur J. K. , Kang J. H. , Shin W. S. , Kang M. W. . ( 1995; ). Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea. . J Korean Med Sci 10:, 314–317.[PubMed] [CrossRef]
    [Google Scholar]
  13. Klugman K. , Koornhof H. J. , Schneerson R. , Cadoz M. , Gilbertson I. T. , Robbins J. B. , Schulz D. , Armand J. . ( 1987; ). Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. . Lancet U 330:, 1165–1169. [CrossRef]
    [Google Scholar]
  14. Klugman K. P. , Koornhof H. J. , Robbins J. B. , Le Cam N. N. . ( 1996; ). Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. . Vaccine 14:, 435–438. [CrossRef] [PubMed]
    [Google Scholar]
  15. Lim S. M. , Jung H.-S. , Kim M. J. , Park D.-W. , Kim W.-J. , Cheong H.-J. , Park S.-C. , Lee K.-C. , Shin Y.- K. . & other authors ( 2007; ). Immunogenicity and safety of Vi capsular polysaccharide typhoid vaccine in healthy persons in Korea. . J Microbiol Biotechnol 17:, 611–615.[PubMed]
    [Google Scholar]
  16. Lowry O. H. , Rosebrough N. J. , Farr A. L. , Randall R. J. . ( 1951; ). Protein measurement with the Folin phenol reagent. . J Biol Chem 193:, 265–275.[PubMed]
    [Google Scholar]
  17. Maslanka S. E. , Gheesling L. L. , Libutti D. E. , Donaldson K. B. , Harakeh H. S. , Dykes J. K. , Arhin F. F. , Devi S. J. , Frasch C. E. . & other authors ( 1997; ). Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. . Clin Diagn Lab Immunol 4:, 156–167.[PubMed]
    [Google Scholar]
  18. Mastroeni P. , Ménager N. . ( 2003; ). Development of acquired immunity to Salmonella . . J Med Microbiol 52:, 453–459. [CrossRef] [PubMed]
    [Google Scholar]
  19. Nolan C. M. , Feeley J. C. , White P. C. Jr , Hambie E. A. , Brown S. L. , Wong K.-H. . ( 1980; ). Evaluation of a new assay for Vi antibody in chronic carriers of Salmonella typhi . . J Clin Microbiol 12:, 22–26.[PubMed]
    [Google Scholar]
  20. Rodríguez T. , Lastre M. , Cedré B. , del Campo J. , Bracho G. , Zayas C. , Taboada C. , Díaz M. , Sierra G. , Pérez O. . ( 2002; ). Standardization of Neisseria meningitidis serogroup B colorimetric serum bactericidal assay. . Clin Diagn Lab Immunol 9:, 109–114.[PubMed]
    [Google Scholar]
  21. Szu S. C. , Li X.-R. , Stone A. L. , Robbins J. B. . ( 1991; ). Relation between structure and immunologic properties of the Vi capsular polysaccharide. . Infect Immun 59:, 4555–4561.[PubMed]
    [Google Scholar]
  22. Szu S. C. , Taylor D. N. , Trofa A. C. , Clements J. D. , Shiloach J. , Sadoff J. C. , Bryla D. A. , Robbins J. B. . ( 1994; ). Laboratory and preliminary clinical characterization of Vi capsular polysaccharide–protein conjugate vaccines. . Infect Immun 62:, 4440–4444.[PubMed]
    [Google Scholar]
  23. Tang S.-S. , Tan W.-S. , Devi S. , Wang L.-F. , Pang T. , Thong K.-L. . ( 2003; ). Mimotopes of the Vi antigen of Salmonella enterica serovar Typhi identified from phage display peptide library. . Clin Diagn Lab Immunol 10:, 1078–1084.[PubMed]
    [Google Scholar]
  24. Wain J. , House D. , Zafar A. , Baker S. , Nair S. , Kidgell C. , Bhutta Z. , Dougan G. , Hasan R. . ( 2005; ). Vi antigen expression in Salmonella enterica serovar Typhi clinical isolates from Pakistan. . J Clin Microbiol 43:, 1158–1165. [CrossRef] [PubMed]
    [Google Scholar]
  25. WHO ( 1973; ). General Requirements for the Sterility of Biological Substances; 25th report. WHO Technical Report Series, No. 530. . Geneva:: World Health Organization;. Annex 4.
  26. WHO ( 1974; ). Requirements for Vi-polysaccharide Typhoid Vaccine. WHO Technical Report. Series, No. 840. . Geneva:: World Health Organization;. Annex 1.
  27. WHO ( 1976; ). Requirements for Meningococcal Polysaccharide Vaccine; 27th report. WHO Technical Report Series, No. 594. . Geneva:: World Health Organization;. Annex 2.
  28. WHO ( 1979; ). The International Pharmacopoeia, 3rd edn, Vol. 1. General Methods of Analysis . . Geneva:: World Health Organization;.
  29. WHO ( 1981; ). Requirements for meningococcal polysaccharide vaccine (Requirements for biological substances no. 23, addendum 1980). . In: WHO Expert Committee on Biological Standardization; 31st report. WHO Technical Report Series, No. 658. Geneva: World Health Organization. Annex 6.
    [Google Scholar]
  30. WHO ( 1994; ). Requirements for Vi Polysaccharide Typhoid Vaccine. WHO Technical Report Series, No. 840. . Geneva:: World Health Organization;. Annex 1.
  31. Yang H. H. , Wu C. G. , Xie G. Z. , Gu Q. W. , Wang B. R. , Wang L. Y. , Wang H. F. , Ding Z. S. , Yang Y. . & other authors ( 2001; ). Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. . Bull World Health Organ 79:, 625–631.[PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.047159-0
Loading
/content/journal/jmm/10.1099/jmm.0.047159-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error